Real-World data on Anti-HER2 therapy for egyptian breast cancer patients
NCT ID NCT07416409
First seen Feb 22, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This study tracked 80 Egyptian women with HER2-positive breast cancer to see how well anti-HER2 drugs like trastuzumab work in everyday care. Researchers measured survival, cancer progression, and side effects. The goal was to understand how these treatments perform in this specific population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dar Al-Salam Cancer Hospital
Cairo, Menia Governorate, Egypt
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-HER2 drugs (trastuzumab, pertuzumab, lapatinib)
What this could lead to
If successful, this study could show how well these drugs work in Egyptian patients, helping doctors choose the best treatment for this population.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also small (80 patients) and completed, so it won't change practice on its own.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.